Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to “Buy” Rating

Kura Oncology (NASDAQ:KURA) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday.

A number of other brokerages have also weighed in on KURA. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. UBS Group dropped their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Finally, BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $7.14 on Wednesday. Kura Oncology has a 12 month low of $6.79 and a 12 month high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $576.59 million, a PE ratio of -3.03 and a beta of 0.85. The stock’s fifty day simple moving average is $7.83 and its 200 day simple moving average is $12.14.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. On average, research analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Insider Buying and Selling

In other news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,729 shares of company stock worth $92,307. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtus ETF Advisers LLC increased its holdings in shares of Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after acquiring an additional 3,061 shares during the last quarter. Harbor Advisors LLC acquired a new position in shares of Kura Oncology in the fourth quarter valued at $87,000. E Fund Management Co. Ltd. bought a new position in shares of Kura Oncology in the fourth quarter valued at about $90,000. Corton Capital Inc. acquired a new stake in shares of Kura Oncology during the 4th quarter worth about $99,000. Finally, Optimize Financial Inc acquired a new stake in shares of Kura Oncology during the 4th quarter worth about $100,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.